Navigation Links
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
Date:5/6/2008

), p<0.0001. Furthermore, over the 24-month treatment period, relapse occurred in 16.5 percent of patients treated with RLAI and 31.3 percent in the quetiapine treatment arm.(6)

Both RLAI and quetiapine had generally comparable safety profiles. Extrapyramidal symptoms (EPS) attributed to medication were observed in 10 percent of the patients receiving RLAI and in six percent of the patients in the quetiapine group. Weight gain was observed in both treatment arms with no statistically significant differences in changes in body weight or BMI versus baseline (seven percent weight gain for RLAI versus 6.2 percent for quetiapine). Potentially prolactin-related adverse events were observed in 16.7 percent of the patients in the RLAI arm and in three percent of patients in the quetiapine arm.

Reasons for withdrawing from the study, other than relapse, were equivalent in both treatment groups except that more withdrawals due to non-compliance/refusing injection were reported for RLAI (three percent) than quetiapine (one percent). The most common serious adverse events were psychiatric symptoms (15 percent with RLAI and 18 percent with quetiapine). Death occurred in three patients treated with RLAI and two with quetiapine. None of the deaths were considered to be possibly or probably related to study drug.

The study was sponsored by Janssen-Cilag, Medical Affairs EMEA.

Separately, an interim analysis from a two-year U.S. observational study also presented today at APA showed patients taking RLAI had significantly improved functioning within three months after starting treatment. That study enrolled 532 patients from 66 community health centers and Veterans Affairs centers in the United States. Data collection occurred at baseline (month 0) and then every three months up to the two years. At the time of this interim analysis, 107 patients had completed the full two-year period.(7)

The U.S. interim analysis showed an overall significant impro
'/>"/>

SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
2. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
8. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
9. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
10. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/pjbxjd/us_aco_it ) ... IT Spending Outlook 2018" report to their offering. ... covered by ACO would grow at a CAGR of ... IT spending has been studied on three main grounds ... on services. Our research provides current market estimation and ...
(Date:5/1/2015)... PRINCETON, N.J. , May 1, 2015 ... it has expanded its current therapeutic focus ... and other serious psychiatric disorders. Braeburn has ... atypical (or second-generation) antipsychotic risperidone for treatment ... risperidone acquisition Braeburn acquires global rights to ...
(Date:5/1/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), an ... markets products that assist healthcare providers in monitoring patients ... the first quarter ended March 31, 2015. ... continued progress with year over year growth of 44% ... said Doug Murphy-Chutorian , M.D., chief executive officer ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5
... Life Spine, a medical device company that designs, develops, ... spinal disorders, announced today amidst consolidations in the industry ... its history. As a full line spine company Life ... sacrum. Aileron™, a minimally invasive adjustable InterSpinous ...
... China, Nov. 4, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... marketer of medical devices worldwide, today announced that it will ... fair to be held between November 16 and 19 in ... H2 C07 at the 43rd World Forum of Medicine - ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 2Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 3
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... a difference. , In this material world, almost everything is ... money, which is why those things should be prioritized above ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... 02, 2015 Kare Visits LLC. launched in ... busy caregivers. Kare Visits offers relief for caregivers by ... facilities. According to the Caregiver Action Network, eight ... of 20 hours a week caring for an elderly or ... to hire a nurse, a caregiver is now empowered to ...
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
(Date:5/1/2015)... 01, 2015 Pioneer Millworks, the largest ... latest in their reclaimed wood products at the 27th ... Javits Center in NYC this May. Their newest offerings, ... much anticipated texture and color to North America's platform ... of texture and color in the design world and ...
Breaking Medicine News(10 mins):Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3
... AstraZeneca (NYSE: AZN ) is aware ... (FDA) posted to its web site -- and subsequently ... Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The PDAC meeting ... provided in supplemental new drug applications (sNDA) for SEROQUEL ...
... to help men and women from the United Kingdom (UK) and Europe who ... has opened its London center. , ... (PRWEB) April 3, 2009 -- In its continued ... who are thinning and balding, Nu/Hart Hair Clinics , a world leader ...
... April 3 Recently, researchers at the University ... conducted a study of U.S. hospitals and discovered that ... year. The study recommended solutions, including location-based technology, to ... of this study come at a time when Versus ...
... WARSAW, Ind., April 3 Zimmer Holdings, Inc. (NYSE: ... 2009 sales and earnings conference call will be broadcast live ... a.m. Eastern Time. A news release detailing the quarterly ... of the conference call.The live audio webcast can be accessed ...
... radiation dose delivered to patients undergoing coronary CT ... using tube current modulation, according to a study ... PA. , The study included 172 patients ... tube current modulation and 95 patients who were ...
... Researchers from Boston University School of Medicine,s (BUSM) ... traits associated with healthy aging and longevity amongst ... in collaboration with scientists from the National Institute ... the Journal of the American Geriatrics Society ...
Cached Medicine News:Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 3Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 4Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 5Health News:Nu/Hart, World Leader in Hair Transplants, Opens London Centre 2Health News:Nu/Hart, World Leader in Hair Transplants, Opens London Centre 3Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 2Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 3Health News:Versus Technology to Showcase Leading Enterprise Patient and Clinical Workflow Solutions at HIMSS 2009 4Health News:Radiation dose can be reduced for 'triple rule-out' coronary CT angiography 2Health News:Researchers identify personality traits 2
... low profile implantable bipolar fixed screw-in ... either the atrium or the ventricle. ... a screwdriver shape stylet which is ... ring tip and fixation screw are ...
... are implantable bipolar extendable/retractable screw-in permanent ... the atrium or the ventricle. The ... extended or retracted by turning the ... an anti-chattering mechanism for steady pacing ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used to occupy an empty hole which is not being used in an implantablepacemaker header....
Medicine Products: